Listen to Dr. Harpreet Wasan commenting on the endpoint of PFS at any site.
Dr. Wasan’s key comments and takeaways:
- Patients in the SIRFLOX study had a bad prognosis, as patients with limited disease outside the liver were allowed to enroll in the study; over 40% of SIRFLOX patients had their primary tumor in situ, and 90% had synchronous disease.
- Patients with synchronous disease often have multiple sites of disease at the first presentation. As the number of visible metastases increases, the number of micro metastases most likely increases as well but cannot be seen at time of diagnosis. Dr. Wasan assumes that the majority of patients had micro metastases outside the liver that progressed upon systemic therapy.